T.E. Bapiro et al. / Biochemical Pharmacology 64 (2002) 1387±1398
1397
enzyme activity and evaluation of metabolic correlation of CYP2D6
probe drugs. Eur J Clin Pharmacol 1996;51:117±22.
quine 4-hydroxylase and dextromethorphan O-demethylation in mi-
crosomes and purified cytochrome P450 isozymes of human liver.
Anal Biochem 1987;162:24±32.
È
[10] Johansson I, Lundqvist E, Bertilsson L, Dahl M, Sjoqvist F, Ingelman-
Sundberg M. Inherited amplification of an active gene in the cyto-
chrome P450 CYP2D locus as a cause of ultra-rapid metabolism of
debrisoquine. Proc Natl Acad Sci USA 1993;90:11825±9.
[11] Zanger UM, Fischer J, Raimundo S, StuÈven T, Evert BO, Schwab M,
Eichelbaum M. Comprehensive analysis of the genetic factors deter-
mining expression and function of hepatic CYP2D6. Pharmacoge-
netics 2001;11:573±85.
[28] Chiu FC, Damani LA, Li RC, Tomlinson B. Efficient high-perfor-
mance liquid chromatographic assay for the simultaneous determina-
tion of metoprolol and two main metabolites in human urine by solid-
phase extraction and fluorescence detection. J Chromatogr B Biomed
Sci Appl 1997;696:69±74.
[29] Houston JB. Utility of in vitro drug metabolism data in predicting in
vivo metabolic clearance. Biochem Pharmacol 1994;47:1469±79.
[30] Crespi CL. Xenobiotic-metabolising human cells as tools for phar-
macological and toxicological research. Adv Drug Res 1995;26:
179±235.
È
[12] Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjoqvist F. Genetic
analysis of the Chinese cytochrome P450 2D locus: characterisation of
variant CYP2D6 genes present in subjects with diminished capacity
for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452±9.
[13] Fukuda T, Nishida Y, Hiroi T, Naohara M, Funae Y, Azuma J. The
decreased in vivo clearance of CYP2D6 substrates by CYP2D6Ã10
might be caused not only by the low-expression but also by low
affinity of CYP2D6. Arch Biochem Biophys 2000;380:303±8.
[14] Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propanolol
disposition in Chinese subjects of different CYP2D6 genotypes. Clin
Pharmacol Ther 1995;58:264±8.
[31] Williams PA, Cosme J, Sridhan V, Johnson EF, McRee DE. Mamma-
lian microsomal cytochrome P450 monooxygenase: structural adapta-
tions for membrane binding and functional diversity. Mol Cell 2000;
5:121±31.
È
[32] Afzelius L, Zamora I, Ridderstrom M, Andersson TB, Karlen A,
Masimirembwa CM. Competitive CYP2C9 inhibitors: enzyme inhibi-
tion studies, protein homology modeling, and three-dimensional
structure±activity relationship analysis. Mol Pharmacol 2001;59:
909±19.
[15] Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD. Formation of
morphine from codeine in Chinese subjects of different CYP2D6
genotypes. Clin Pharmacol Ther 1996;60:177±82.
[33] Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and
validation of a genetic algorithm for flexible docking. J Mol Biol
1997;267:727±48.
Â
[16] Yue QY, Zhong ZH, Tybring G, Dalen P, Dahl ML, Bertilsson L,
È
Sjoqvist F. Pharmacokinetics of nortriptyline and its 10-hydroxy
[34] Venkatakrishnan K, Von Moltke LL, Court MH, Harmatz JS, Crespi
CL, Greenblatt DJ. Comparison between cytochrome P450 (CYP)
content and relative activity approaches to scaling from cDNA-ex-
pressed CYPs to human liver microsomes: ratios of accessory proteins
as sources of discrepancies between the approaches. Drug Metab
Dispos 2000;28:1493±505.
metabolite in Chinese subjects of different CYP2D6 genotypes. Clin
Pharmacol Ther 1998;64:384±90.
[17] Wood AJJ, Zhou HH. Ethnic differences in drug disposition and
responsiveness. Clin Pharmacokinet 1991;20:350±73.
[18] Masimirembwa CM, Persson I, Bertilsson L, Hasler J, Ingleman-
Sundberg M. A novel mutant variant of the CYP2D6 gene (CY-
P2D6Ã17) common in a black African population: association with
diminished hydroxylase activity. Br J Clin Pharmacol 1996;42:713±9.
[19] Wan YY, Poland RE, Han G, Konishi T, Zheng Y, Berman N, Lin K.
Analysis of the CYP2D6 gene polymorphism and enzyme activity in
African-Americans in southern California. Pharmacogenetics 2001;
11:489±99.
[35] Gotoh O. Substrate recognition sites in cytochrome P450 family 2
(CYP2) proteins inferred from comparative analyses of amino acid
and coding nucleotide sequences. J Biol Chem 1992;267:83±90.
[36] de Groot MJ, Vermeulen NPE, Kramer JD, van Acker FAA, Donne-Op
den Kelder GM. A three-dimensional protein model for human
cytochrome P450 2D6 based on the crystal structures of P450 101,
P450 102, P450 108. Chem Res Toxicol 1996;9:1079±91.
[37] Poli-Scaife S, Attias R, Dansette PM, Mansuy D. The substrate
binding site of human liver cytochrome P450 2C9: an NMR study.
Biochemistry 1997;36:12672±82.
[20] Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A
combination of mutations in the CYP2D6Ã17 (CYP2D6Z) allele causes
alterations in enzyme function. Mol Pharmacol 1997;52:1034±40.
[21] Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-
Salguero P, Buters JTM, Gelboin HV, Gonzalez FJ, Idle JR, Daly
AK. Comparison of substrate metabolism by wild type CYP2D6
protein and a variant containing methionine, not valine, at position
374. Pharmacogenetics 1995;5:234±43.
[38] Schlichting I, Berendzen J, Chu K, Stock AM, Maves SA, Benson DE,
Sweet RM, Ringe D, Petsko GA, Sligar SG. The catalytic pathway
of cytochrome P450cam at atomic resolution. Science 2000;287:
1615±22.
[39] Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedisk
A. Characterisation of cytochrome P450 2D6.1 (CYP2D6),
CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 sub-
strates dextromethorphan, bufuralol, and debrisoquine. Drug Metab
Dispos 2002;30:595±601.
[22] Pearce RE, Mcintyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock
PL, Cook DC, Burton AL, Latham J, Nevins C, Parkinson A. Effects of
freezing, thawing, and storing human liver microsomes on cytochrome
P450 activity. Arch Biochem Biophys 1996;331:145±69.
[23] Gietz D, St Jean A, Woods RA, Schiestl RH. Improved method for
high efficiency transformation of intact yeast cells. Nucleic Acids Res
1992;20:142±5.
[40] Poolsup N, Wan AL, Knight TL. Pharmacogenetics and psychophar-
macotherapy. J Clin Pharm Ther 2000;25:197±220.
[41] Schadel M, Wu D, Otton V, Kalow W, Sellers EM. Pharmacokinetics
of dextromethorphan and metabolites in humans: influence of the
CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol
1995;15:263±9.
È
[24] Masimirembwa CM, Otter C, Berg M, Jonsson M, Leidvik B, Jonsson
È
E, Johansson T, Backman A, Edlund A, Andersson TB. Heterologous
expression and kinetic characterisation of human cytochrome P450:
validation of a pharmaceutical tool for drug metabolism research.
Drug Metab Dispos 1999;27:1117±22.
[42] Jazwinska-Tarnawska E, Orzechowska-Juzwenko K, Niewinski P,
Rzemislawska Z, Loboz-Grudzien K, Dmochowska-Perz M, Slawin
J. The influence of CYP2D6 polymorphism on the antiarrhythmic
efficacy of propafenone in patients with paroxysmal atrial fibrillation
during 3 months propafenone prophylactic treatment. Int J Clin
Pharmacol Ther 2001;39:288±92.
[25] Omura T, Sato R. The carbon monoxide-binding pigment of liver
microsomes: evidence for its hemoprotein nature. J Biol Chem 1964;
239:2370±8.
[26] Markwell MAK, Has SM, Bieber LL, Tolbert NE. A modification of
the Lowry procedure to simplify protein determination in membrane
and lipoprotein samples. Anal Biochem 1978;87:206±10.
[27] Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. High performance
liquid chromatographic assays for bufuralol 10-hydroxylase, debriso-
Â
[43] von Bahr C, Movin G, Nordin C, Lid en A, Hammaarlund-Udenaes M,
È
Hedberg A, Ring H, Sjoqvist F. Plasma levels of thioridazine and
metabolites are influenced by the debrisoquine hydroxylation pheno-
type. Clin Pharmacol Ther 1991;49:234±40.